Massively Parallel Sequencing to Identify Microbiological Organisms in

Status Completed

Clinical Trial Summary

Patients who are post hematopoietic stem cell transplantation who require a bronchoalveolar lavage (BAL) for standard clinical car will have extra fluid collected and sent for massively parallel sequencing to see if it is as sensitive for detecting a microbial pulmonary infection compared to standard cultures.

Clinical Trial Description

5.1 Subjects will undergo bronchoscopy and BAL based on clinical indications. Techniques and equipment will be per current clinical practice at Westchester Medical Center (WMC). The bronchoscope is usually introduced either via an artificial airway (endotracheal tube or laryngeal mask airway). The lavage is performed with sterile normal saline. The site of performing the lavage is selected based on radiologic or clinical data and on the appearance of the airways during the bronchoscopy. The typical volume of the lavage is 3 aliquots of 1 ml/kg each, with a max of 20 ml per aliquot. 5.2 When 10 ml or more of BAL fluid is received by the WMC laboratory, the BAL fluid will be divided by the WMC laboratory for all physician ordered clinical laboratory tests and for massively parallel sequencing research tests. This will ensure that sufficient BAL material is available for all clinical tests. 5.3 The BAL fluid for research will be held by the WMC laboratory and picked up by research personnel for processing at New York Medical College Genomics Core Facility. 5.4 The research portion will be further divided for isolation of viral, bacterial, and fungal nucleic acid isolation. A control sample of fluid used for the BAL will be prepared in parallel. Bacterial/fungal DNA and viral DNA and RNA will be isolated. Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.11 DNA sequences present in both the patient and control samples will be discarded as contaminant. The preponderant organism(s) identified will be matched to the results of the culture based techniques used to verify the culture independent results. ;

Study Design

Related Conditions & MeSH terms

Pulmonary Infection

Clinical Trial Details

NCT number	NCT03995030
Study type	Observational
Source	New York Medical College
Contact
Status	Completed
Phase
Start date	September 15, 2016
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03687177` - Visual Cue as Prevention of Pulmonary Infection Under Mechanical Ventilation	N/A
Recruiting	`NCT05552872` - Study on Diagnosis Value of mNGS Technology Among Diabetic Patients With Pulmonary Infections
Not yet recruiting	`NCT04583046` - Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation	N/A
Recruiting	`NCT04624490` - Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Phase 1
Recruiting	`NCT05505487` - Construction and Effect Evaluation of Integrated Care Model for Pulmonary Infection in Stroke Patients With Tracheotomy	N/A
Terminated	`NCT04348513` - Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection	Phase 2
Completed	`NCT03438383` - Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery	N/A
Completed	`NCT03933878` - Rapid Detection of Airway Pathogens for Lung Transplantation
Completed	`NCT05844215` - MMP-9, TIMP-9 in Lung Imaging and Functional of COVID-19
Completed	`NCT02779595` - Change of Regional Ventilation During Spontaneous Breathing After Lung Surgery	N/A
Recruiting	`NCT06368388` - Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force
Recruiting	`NCT04457609` - Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients	Phase 1
Completed	`NCT01525121` - Expiratory Rib Cage Compression in Mechanically Ventilated Patients	N/A
Active, not recruiting	`NCT03617393` - Study on Appropriate Technology of Standardized Diagnosis and Treatment for Diabetic Patients With Pulmonary Infections
Completed	`NCT05226403` - COVID-19 : Pulmonary Ultrasound in Primary Care
Terminated	`NCT04422691` - Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
Completed	`NCT04553315` - the Effect of Chest Expansion Exercises on Pleural Effusion	N/A
Recruiting	`NCT06282835` - Eravacycline Combination Therapy for MRAB
Completed	`NCT02419196` - Perioperative Change of Regional Ventilation During Spontaneous Breathing	N/A
Completed	`NCT01058356` - Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Massively Parallel Sequencing to Identify Microbiological Organisms in Bronchoalveolar Lavage Fluid

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms